Thomas Appio, Bausch Health CEO

Bausch Health as­serts push to 'vig­or­ous­ly' de­fend Xi­fax­an patent lit­i­ga­tion 

Bausch Health will con­tin­ue lit­i­gat­ing over its Xi­fax­an drug, threat­en­ing to ap­peal all the way up to the US Court of Ap­peals for the Fed­er­al Cir­cuit.

The Que­bec-based com­pa­ny, through its gas­troen­terol­o­gy busi­ness Sal­ix Phar­ma­ceu­ti­cals, said it will file an ap­peal if the fi­nal or­der is con­sis­tent with an oral or­der in a Delaware dis­trict court last week cen­tered around a case against Nor­wich Phar­ma­ceu­ti­cals.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.